Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Screaming. Crying. Throwing up. David Harbour you are over,” one person tweeted in response to Lily’s subtle joke.

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s ...

With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa. Lilly on Sunday ...

Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ...

Evangeline Lilly breaks her silence on years-long health battle following an unfortunate accident at the beach. The actress, who announced her exit from Hollywood last June, got vulnerable with fans ...

Citi Annual Global Healthcare Conference 2025 December 2, 2025 10:30 AM ESTCompany ParticipantsIlya Yuffa - Executive VP ...

From in-depth workshops to networking opportunities, the 44th edition of the Original Lilly Conference on College Teaching has a little bit of everything for educators, no matter the experience level.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...